I think the authorization serves two purposes: 1) to allow the spin off to occur, in which the authorized shares would fill the needed capitalization of the spinoff company and 2) attract institutions and hedge funds for investment purposes. Remember that spin offs are used mainly for the purpose of attracting big pockets when it comes to investments. If they do spin off, the new company would automatically be on the radar on major institution houses, which would stop the worrying about dilution. I have been thinking about what part of the company would actually serve us better in that scenario, and i have come to the conclusion that MANF would be the best because that part of the business is a couple years at least away from actually being commercialized. Because Lympro is right at the door step of commercialization, the revenues that stem from that exposure would best serve the stock in the short term. But, I also realize the big big bucks and value is in the MANF set of products, it is a coin toss. Granted I am still trying to catch up, I makes sense to keep guaranteed revenue generating assets with AMBS, and spin off the future generating aspect of the business so institutions can finance the growth on the open market with the purpose of buying a equity position. Works for all around, and quells the worries of further dilution and shareholder value. Any thoughts?